Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEN-K vs CALCIUM GLUCEPTATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride is a potassium supplement that replaces potassium ions in the body, essential for maintaining intracellular osmotic pressure, acid-base balance, and nerve conduction. It acts as a cofactor for numerous enzymes and is critical for myocardial and skeletal muscle contraction.
Calcium gluceptate is a calcium salt that dissociates to provide calcium ions, which are essential for various physiological processes including nerve conduction, muscle contraction, blood coagulation, and cardiac function. It acts as a calcium replenisher.
Treatment and prevention of hypokalemia,Hypokalemia associated with diuretic therapy,Hypokalemia in patients with digitalis toxicity
Treatment of hypocalcemia,Calcium supplementation in patients requiring parenteral calcium,Treatment of hypermagnesemia,Cardiac resuscitation (as an adjunct),Treatment of calcium channel blocker overdose
10 m Eq (one tablet) orally once daily or as directed by physician.
IV: 2-4 mg/kg elemental calcium (5-10 m L of 0.45 m Eq/m L solution) administered slowly over 10-20 minutes. May repeat if needed. Maximum dose: 20 m L per infusion.
Terminal elimination half-life is approximately 30-60 minutes; clinical context: short half-life necessitates frequent dosing for maintenance of potassium levels.
Terminal elimination half-life: 2-4 hours (normal renal function); prolonged to 12-24 hours in renal impairment.
Potassium chloride is not metabolized; it is absorbed and excreted primarily by the kidneys. Approximately 90% is eliminated in urine, with the remainder in feces and sweat.
Calcium gluceptate is not metabolized; it dissociates into calcium ions and gluceptate. Calcium ions are excreted primarily in feces and urine, with renal handling involving reabsorption and secretion.
Renal: >90% excreted unchanged by the kidneys; fecal: <5%
Renal: >90% excreted unchanged in urine. Biliary/fecal: <5%.
Minimal (<10%); not significantly bound to plasma proteins.
~45% bound to albumin.
Approximately 0.2-0.4 L/kg; reflects distribution primarily in extracellular fluid.
0.15-0.25 L/kg; represents distribution mainly in extracellular fluid.
Oral: 100% (potassium chloride is well absorbed); IV: 100%.
IV: 100%; IM: not well characterized; oral: negligible (absorbed poorly, systemic bioavailability <1% as calcium gluceptate dissociates in GI tract).
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min, reduce dose by 50% and monitor serum potassium. Use with caution in mild impairment.
GFR >50: No adjustment. GFR 30-50: Reduce dose by 25%. GFR <30: Reduce dose by 50% and monitor serum calcium closely. Dialysis: Dose after hemodialysis.
No specific adjustment; however, use with caution in severe hepatic impairment due to risk of hyperkalemia.
No dose adjustment required for hepatic impairment. However, monitor ionized calcium in severe hepatic failure due to altered binding proteins.
Not established; safety and efficacy in pediatric patients not determined.
Neonates and infants: 100-200 mg elemental calcium/kg/day IV divided every 6 hours. Children: 200-500 mg elemental calcium/kg/day IV divided every 6 hours. Maximum: 1 g elemental calcium per dose.
Start at 5 m Eq orally daily; titrate slowly and monitor serum potassium due to age-related renal function decline.
Use lower initial doses (e.g., 1-2 mg/kg elemental calcium) due to reduced renal function and increased risk of hypercalcemia. Monitor serum calcium and phosphate levels.
None
No FDA black box warning.
Hyperkalemia risk, especially in patients with renal impairment,Cardiac effects: risk of arrhythmias with rapid correction or high doses,Gastrointestinal reactions: ulceration, bleeding, perforation with solid oral formulations,Use with caution in patients with renal insufficiency, adrenal insufficiency, diabetes, or cardiac disease,Monitor serum potassium levels and ECG during therapy
Risk of hypercalcemia, especially in patients with renal impairment,Avoid rapid intravenous administration to prevent cardiac arrest,Use with caution in patients with sarcoidosis or digitalis toxicity,Monitor serum calcium levels during therapy,Extravasation may cause tissue necrosis
Hyperkalemia,Severe renal impairment with oliguria or anuria,Untreated Addison's disease,Solid oral potassium supplements in patients with delayed gastrointestinal transit
Hypercalcemia,Hypersensitivity to calcium gluceptate or any component,Ventricular fibrillation,Patients with known calcium-containing calculi
Avoid high-potassium foods (bananas, oranges, spinach, potatoes, tomatoes) in large amounts; limit salt substitutes containing potassium chloride. Take with food to minimize GI irritation.
Avoid high-calcium foods (dairy, fortified cereals) during acute therapy to prevent hypercalcemia. Limit vitamin D-rich foods (fatty fish, fortified milk). Do not take oral calcium within 1 hour of iron or thyroid medications. Avoid excessive caffeine and alcohol.
No known teratogenic effects based on available data. Potassium supplementation does not increase risk of congenital anomalies above baseline. However, avoid hyperkalemia in pregnant women as high potassium levels may pose risks. First trimester: No evidence of fetal harm. Second trimester: Monitor maternal potassium levels. Third trimester: Adjusted potassium requirements may occur due to increased renal clearance; maintain normokalemia.
Calcium gluceptate is a calcium salt used for calcium supplementation. No specific teratogenic effects are reported; calcium is essential for fetal development. First trimester: No increased risk of major malformations. Second and third trimesters: Adequate intake supports fetal skeletal mineralization; excess may cause hypercalcemia in the infant. No known teratogenicity.
Potassium is excreted into breast milk in amounts not likely to cause adverse effects in nursing infants. The M/P ratio is approximately 0.4. Supplementation at physiological doses is considered compatible with breastfeeding. Monitor maternal serum potassium to avoid excessive dosage.
Calcium gluceptate is considered safe during breastfeeding. Calcium is naturally present in breast milk; supplementation does not significantly alter milk calcium levels. M/P ratio not established, but endogenous calcium transport suggests minimal risk. Use with caution in mothers with hypercalcemia.
No specific dose adjustment required for TEN-K based on pregnancy alone. However, pregnancy can increase renal clearance of potassium, potentially lowering serum levels. Monitor potassium levels and adjust dose if hypokalemia develops. Typical dose range: 20-100 m Eq/day, titrated according to serum potassium. Avoid excessive dosing to prevent hyperkalemia.
No specific dose adjustment required in pregnancy; maintain recommended daily intake (1000-1300 mg elemental calcium). Pharmacokinetic changes in pregnancy (increased absorption, renal clearance) may slightly alter requirements, but standard doses are safe. Intravenous use should be adjusted based on serum calcium monitoring.
TEN-K is a high-dose potassium chloride formulation (10 m Eq per tablet) used for hypokalemia. Do not split or crush tablets; they are extended-release to prevent GI irritation. Monitor serum potassium and renal function; avoid in severe renal impairment or hyperkalemia. Consider potential for esophageal ulceration if tablet lodges.
Calcium gluceptate is used for acute hypocalcemia, hyperkalemia cardiotoxicity, and hypermagnesemia. Administer IV slowly (0.5-1 m L/min) to avoid arrhythmias; monitor ECG during infusion. Do not mix with bicarbonate, phosphate, or sulfate-containing solutions. Extravasation causes tissue necrosis; use central line for peripheral therapy. Correct hypomagnesemia before calcium therapy to prevent refractory hypocalcemia.
Take with a full glass of water and with food or after a meal to reduce stomach upset.,Swallow tablets whole; do not crush, chew, or split them.,Avoid salt substitutes or potassium-containing supplements unless directed by your doctor.,Report signs of hyperkalemia: muscle weakness, irregular heartbeat, tingling in hands/feet.,Store at room temperature, away from moisture and heat.
Report any burning or pain at injection site immediately.,Avoid taking calcium supplements or antacids without consulting your doctor.,Tell your doctor if you have kidney stones, parathyroid disorders, or heart disease.,Do not stop other calcium medications abruptly.,Seek emergency care for difficulty breathing or chest tightness after infusion.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEN-K vs CALCIUM GLUCEPTATE, answered by our medical review team.
TEN-K is a Electrolyte supplement that works by Potassium chloride is a potassium supplement that replaces potassium ions in the body, essential for maintaining intracellular osmotic pressure, acid-base balance, and nerve conduction. It acts as a cofactor for numerous enzymes and is critical for myocardial and skeletal muscle contraction.. CALCIUM GLUCEPTATE is a Electrolyte Supplement that works by Calcium gluceptate is a calcium salt that dissociates to provide calcium ions, which are essential for various physiological processes including nerve conduction, muscle contraction, blood coagulation, and cardiac function. It acts as a calcium replenisher.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEN-K and CALCIUM GLUCEPTATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEN-K is: 10 m Eq (one tablet) orally once daily or as directed by physician.. The standard adult dose of CALCIUM GLUCEPTATE is: IV: 2-4 mg/kg elemental calcium (5-10 m L of 0.45 m Eq/m L solution) administered slowly over 10-20 minutes. May repeat if needed. Maximum dose: 20 m L per infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEN-K and CALCIUM GLUCEPTATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEN-K is classified as Category C. No known teratogenic effects based on available data. Potassium supplementation does not increase risk of congenital anomalies above baseline. However, avoid hyperkalemia in pregna. CALCIUM GLUCEPTATE is classified as Category C. Calcium gluceptate is a calcium salt used for calcium supplementation. No specific teratogenic effects are reported; calcium is essential for fetal development. First trimester: No. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.